Healthtech startup CARPL.ai has secured $10 million in Series A funding to expand its radiology AI platform globally. The investment, led by the International Finance Corporation, follows a $6 million seed round in 2024. The capital will support product development as the company moves into new medical fields like pathology and genomics.
Detailed Coverage
CARPL.ai, a healthtech company focused on artificial intelligence for medical imaging, announced on July 25, 2026, that it has raised $10 million in a Series A funding round. This investment was led by the International Finance Corporation (IFC), which acts as the private sector investment arm of the World Bank Group. Existing investor Stellaris Venture Partners also participated in the round.
Strategic Use of Capital
The company intends to use the fresh capital to accelerate its product roadmap and extend its commercial reach. CARPL.ai plans to broaden its presence in key international markets, including North America, Europe, Latin America, and the Asia-Pacific region. Since its inception in 2021 by founder Vidur Mahajan, the company has operated as a vendor-neutral platform. This allows healthcare institutions to connect with and manage various AI tools through a single interface, rather than integrating multiple individual systems separately.
Business Model and Market Reach
CARPL.ai currently offers access to more than 300 AI applications developed by over 100 different partners. Its platform is designed to help radiologists test, deploy, and monitor these tools in a clinical setting. According to company data, the platform is already being used by four of the five largest private radiology groups globally. It also maintains a presence in public health systems across several countries, including India, Singapore, Brazil, Spain, and the United Arab Emirates.
Growth and Future Outlook
This Series A round marks a significant step following the company’s $6 million seed funding in February 2024, which was also led by Stellaris Venture Partners. The startup is now looking to diversify its service offerings beyond radiology. Management has indicated plans to apply its platform architecture to fields such as pathology, genomics, and general medicine.
For investors observing the healthtech sector, the core monitorable remains the company’s ability to successfully translate its radiology-focused user base into these new medical specialties. While the platform’s vendor-neutral design provides a potential business advantage by simplifying integration for hospitals, the company will face competition from both specialized AI developers and established medical imaging hardware companies that are increasingly embedding their own AI solutions into their products. The pace of international expansion and the speed at which it can integrate new medical data types will be key areas to track as the company scales its operations.